A Phase 1 Randomized, Double-Blind, Placebo-Controlled Crossover Study to Evaluate the Pharmacokinetics and Safety of JNJ-54452840 Following Single Intravenous Doses to Healthy Japanese and Caucasian Subjects
Phase of Trial: Phase I
Latest Information Update: 05 Aug 2015
At a glance
- Drugs Mibenratide (Primary)
- Indications Heart failure
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 05 Aug 2015 Results published in the Clinical Pharmacokinetics.
- 04 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 14 Mar 2014 Planned End Date changed from 1 Dec 2013 to 1 Sep 2014 as reported by ClinicalTrials.gov record.